Dr. Mathieu Crupi

Dr. Crupi obtained his PhD under the supervision of Dr. Lois Mulligan in the Department of Pathology and Molecular Medicine at Queen’s University. He studied the underlying molecular mechanisms of inherited thyroid cancers, neuroblastoma, lung and pancreatic cancers. During his PhD, Mathieu founded Let's Talk Cancer, a day symposium for highschool students to learn about cancer prevention and local research from young scientists. He built a partnership between Let's Talk Science and the Canadian Cancer Society that allowed for these events to spread across Canada.

His postdoctoral research, under the guidance of Drs. John Bell and Carolina Ilkow at the Ottawa Hospital Research Institute, focused on oncolytic virus-driven immunotherapeutic strategies to enhance survival of colorectal and ovarian cancer patients. These included: engineered T-Cell Engagers, microRNA-mediated synthetic lethal approaches, and inducible cytokines. During the pandemic, he and his colleagues also generated vaccines against SARS-CoV-2 and cancer. 

He is now Lead of Personalized Biotherapeutics at the OHRI Biotherapeutics Manufacturing Centre. His team is establishing the manufacturing for Tumour-Infiltrating Lymphocyte (TIL) and chimeric antigen receptor T-cell (CAR T) cell therapies for upcoming clinical trials in Ottawa. In addition, he is the project manager for correlative studies with PERIOP-06, a multi-site clinical trial coordinated across Ontario and led by Dr. Rebecca Auer. 

Mathieu is also a member of the BioCanRx Scientific Program Committee for the Summit4CI conference. He hopes to inspire HQP to join him in eliminating cancer and fear of the disease through research, mentorship, outreach and fundraising initiatives.Mathieu obtained his PhD under the supervision of Dr. Lois Mulligan in the Department of Pathology and Molecular Medicine at Queen’s University. He studied the underlying molecular mechanisms of inherited thyroid cancers, neuroblastoma, lung and pancreatic cancers. During his PhD, Mathieu founded Let's Talk Cancer, a day symposium for highschool students to learn about cancer prevention and local research from young scientists. He built a partnership between Let's Talk Science and the Canadian Cancer Society that allowed for these events to spread across Canada.

His postdoctoral research, under the guidance of Drs. John Bell and Carolina Ilkow at the Ottawa Hospital Research Institute, focused on oncolytic virus-driven immunotherapeutic strategies to enhance survival of colorectal and ovarian cancer patients. These included: engineered T-Cell Engagers, microRNA-mediated synthetic lethal approaches, and inducible cytokines. During the pandemic, he and his colleagues also generated vaccines against SARS-CoV-2 and cancer. 

He is now Lead of Personalized Biotherapeutics at the OHRI Biotherapeutics Manufacturing Centre. His team is establishing the manufacturing for Tumour-Infiltrating Lymphocyte (TIL) and chimeric antigen receptor T-cell (CAR T) cell therapies for upcoming clinical trials in Ottawa. In addition, he is the project manager for correlative studies with PERIOP-06, a multi-site clinical trial coordinated across Ontario and led by Dr. Rebecca Auer. 

Mathieu is also a member of the BioCanRx Scientific Program Committee for the Summit4CI conference. He hopes to inspire HQP to join him in eliminating cancer and fear of the disease through research, mentorship, outreach and fundraising initiatives.